Skip to main content
Premium Trial:

Request an Annual Quote

Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment

NEW YORK (GenomeWeb News) — Epizyme today announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

The goal of the project, Epizyme said, is to identify lymphoma patients with non-wild type EZH2, including the Y641 mutation. In a study published in September in Nature Chemical Biology, Epizyme researchers demonstrated that lymphomas with genetic alterations of EZH2 require H3K27 methylation activity to proliferate, suggesting that EZH2 is a driving oncogene in these cancers and thus a potential therapeutic target.

Eisai and Epizyme are working together to develop an EZH2 inhibitor as a personalized therapeutic for patients, while Roche will develop a PCR-based assay to detect mutations in the gene to potentially select patients for therapy with the inhibitor.

Additional details of the partnership were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.